BBOT vs SMMT
BBOT: BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including KRAS-driven lung and pancreatic cancers. SMMT: Oncology-focused biotech developing ivonescimab, a first-in-class bispecific antibody combining PD-1 immunotherapy with anti-VEGF anti-angiogenesis, with Phase III trials underway in lung and colorectal cancers.
Side-by-side fundamentals
| Metric | BBOT | SMMT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $8.90 | $14.74 | |
| Market cap as of 2026-07-23 | $701M | $11.4B | |
| P/E as of 2026-07-23 | 148.50 | n/a | |
| PEG as of 2026-07-23 | n/a | -0.02 | |
| Net margin as of 2026-07-23 | n/a | -9027.1% | |
| Operating margin as of 2026-07-23 | n/a | -8108.3% | |
| ROE as of 2026-07-23 | +2.5% | -291.2% | BBOT higher |
| ROA as of 2026-07-23 | +2.4% | -243.1% | BBOT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 0.82 | -1.35 | |
| 1-year return as of 2026-07-22 close | -18.7% | -44.5% | BBOT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.